Trial
NCT07073183
Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
CureVac
Collaborators
—
Condition
Squamous NSCLC
Intervention
CV09070101 mRNA vaccine (CVHNLC) 50 µg
Why stopped
In accordance with 21 CFR 312.38, CureVac is herewith withdrawing IND No. 031346 for CV09070101 (referred to as CVHNLC) for the indication of squamous Non-Small-Cell Lung Cancer (sqNSCLC), following the strategic decision to not pursue the CVHNL
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-29